Based on the Phase 1/2 study data, can you discuss the significance of all 12 patients achieving islet cell engraftment and glucose-responsive insulin production by Day 90? How does this impact our understanding of VX-880's potential as a treatment for T1D?

All patients in the study achieved ADA-recommended HbA1c levels below 7.0% and over 70% time-in-range. How do these results compare to current standards of care, and what do they imply for the long-term management of T1D?

With 11 out of 12 patients reducing or eliminating their use of exogenous insulin, what are the broader implications for patient quality of life and the potential to lessen the daily burden of T1D management?

Three patients with at least 12 months of follow-up met the primary endpoint of eliminating SHEs. How critical is this outcome in terms of patient safety and reducing the risk of life-threatening hypoglycemic episodes?

The study reported that VX-880 was generally well tolerated, with most adverse events being mild or moderate. How does this safety profile compare to other advanced therapies for T1D, and what are the main considerations for patients?

VX-880 has received Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations by the FDA, as well as PRIME designation by the EMA. What do these designations mean for the future development and potential approval of VX-880?

Considering the current treatment landscape for T1D, how does VX-880 compare to other emerging therapies, particularly in terms of its potential to restore pancreatic islet cell function and regulate glucose levels?

The study has been expanded to enroll approximately 37 participants. What do you foresee as the next steps in pivotal development, and how might VX-880 eventually impact the broader T1D population if it proves to be a successful therapy?